{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:03:27Z","timestamp":1784873007328,"version":"3.55.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Deliv."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Messenger RNA vaccines and gene therapies enable rapid and programmable biological intervention, but their therapeutic durability remains variable. Existing nanomedicine research primarily evaluates delivery efficiency, targeting, RNA protection and early protein expression, which do not fully explain why some biological effects persist while others rapidly decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This Hypothesis and Theory article presents a narrative conceptual synthesis of peer-reviewed literature on lipid nanoparticle delivery, mRNA vaccinology, RNA therapeutics, genome editing, trained innate immunity, epigenetic regulation and regenerative medicine. Evidence was integrated to develop an operational and falsifiable framework for evaluating the contribution of nanocarriers to therapeutic durability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We propose the Biological Memory Buffer Hypothesis, according to which programmable nanocarriers may influence biological systems that encode, maintain or recall therapeutic information after RNA delivery. The framework distinguishes payload persistence from biological-outcome persistence and introduces three measurable constructs: therapeutic memory engineering, nanocarrier memory capacity and the therapeutic persistence window. It further proposes matched-cargo and matched-early-exposure experiments, candidate monophasic and biphasic decay models, a minimum durability reporting set and safety monitoring for maladaptive innate immune imprinting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The framework does not assume that adaptive immune memory, trained immunity, epigenetic regulation and regenerative repair share a single molecular mechanism. Rather, it treats them as distinct biological substrates with a common functional relevance to durability. The hypothesis is falsifiable: failure to detect reproducible carrier-attributable differences under matched conditions would argue against nanocarrier memory capacity as an independent determinant. Incorporating longitudinal, tissue-specific and host-stratified durability measurements may support the rational development of longer-lasting RNA vaccines and gene therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fddev.2026.1902184","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:36:34Z","timestamp":1784871394000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The biological memory buffer hypothesis: can programmable nanocarriers shape cellular memory to improve the durability of mRNA vaccines and gene therapies?"],"prefix":"10.3389","volume":"6","author":[{"given":"Okechukwu Paul-Chima","family":"Ugwu","sequence":"first","affiliation":[{"name":"Department of Research, Publication and Extension, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinyere Nneoma","family":"Ugwu","sequence":"additional","affiliation":[{"name":"Department of Research, Publication and Extension, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godson Emeka","family":"Anyanwu","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Biomedical Sciences, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Basajja","sequence":"additional","affiliation":[{"name":"Department of Research, Publication and Extension, Kampala International University","place":["Kampala, Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann Chiamaka","family":"Ebuoh","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy, State University of Medical and Applied Sciences","place":["Igbo Eno, Enugu State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e167955","DOI":"10.1172\/JCI167955","article-title":"Durability of immune responses to mRNA booster vaccination against COVID-19","volume":"133","author":"Arunachalam","year":"2023","journal-title":"J. Clin. Investigation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/s41467-025-58523-w","article-title":"Liposomal lipid nanoparticles for extrahepatic delivery of mRNA","volume":"16","author":"Cheng","year":"2025","journal-title":"Nat. Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","article-title":"Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors","volume":"20","author":"Hofstraat","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101231","DOI":"10.1016\/j.omtm.2024.101231","article-title":"CRISPR-based gene therapies: from preclinical to clinical treatments","volume":"32","author":"Laurent","year":"2024","journal-title":"Mol. Ther. Methods & Clin. Dev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. & Mol. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"115291","DOI":"10.1016\/j.addr.2024.115291","article-title":"Lipid nanoparticles for RNA delivery: self-assembling vs driven-assembling strategies","volume":"208","author":"Nele","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines: a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1089\/hum.2024.106","article-title":"Lipid nanoparticles for nucleic acid delivery beyond the liver","volume":"35","author":"Saber","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"115175","DOI":"10.1016\/j.addr.2023.115175","article-title":"The immunostimulatory nature of mRNA lipid nanoparticles","volume":"205","author":"Sharma","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41578-021-00289-3","article-title":"Regulating trained immunity with nanomedicine","volume":"6","author":"van Leent","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7264","DOI":"10.1039\/D3NR06099C","article-title":"Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines","volume":"16","author":"Wu","year":"2024","journal-title":"Nanoscale"}],"container-title":["Frontiers in Drug Delivery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1902184\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:36:35Z","timestamp":1784871395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1902184\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":21,"alternative-id":["10.3389\/fddev.2026.1902184"],"URL":"https:\/\/doi.org\/10.3389\/fddev.2026.1902184","relation":{},"ISSN":["2674-0850"],"issn-type":[{"value":"2674-0850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1902184"}}